ECS Botanics has commenced commercial sales of Gelonoidz #20, its first Australian-grown Terphogz cultivar, marking a key step in expanding its premium medicinal cannabis portfolio with plans for more cultivars in FY27.
- Gelonoidz #20 launched with 23% THC and 2.8% terpenes
- Product developed via ECS’s phenotype selection using licensed Terphogz genetics
- Terphogz endorses the quality and phenotype selection
- Commercial production underway to support domestic and export markets
- Up to three Terphogz cultivars expected in FY27
Gelonoidz #20 Debuts as Premium Australian-Grown Terphogz Product
ECS Botanics (ASX:ECS) has officially launched Gelonoidz #20, the first Australian-grown product developed from Terphogz genetics, commencing commercial sales on 22 June 2026. This premium dried flower boasts a 23% THC label claim and approximately 2.8% total terpene content, positioning it firmly within the high-end medicinal cannabis segment.
The product is the result of an extensive phenotype selection program undertaken by ECS using licensed Terphogz genetics, with the final cultivar chosen for its terpene profile, flower quality, and suitability for premium medicinal applications. Terphogz itself has reviewed and endorsed the selected phenotype and finished flower quality, providing a notable stamp of approval on ECS’s cultivation capabilities.
Commercial Scale Production and Market Ambitions
Initial commercial production of Gelonoidz #20 is complete, with further cultivation already underway to meet both domestic demand and potential export opportunities. ECS’s mixed-light cultivation platform in Northwest Victoria demonstrates its ability to consistently produce premium flower at commercial scale, leveraging Australian expertise combined with globally recognised genetics.
The launch aligns with ECS’s broader strategy to expand its premium branded portfolio. The company anticipates releasing up to three Terphogz cultivars during FY27, signalling a sustained commitment to building a differentiated range of traceable, high-quality Australian-grown medicinal cannabis products.
Strategic Implications for ECS’s Growth Trajectory
Managing Director Nan-Maree Schoerie highlighted the significance of the launch, emphasising the control ECS retains over quality, consistency, and phenotype selection by cultivating Terphogz genetics in-house. She described Gelonoidz #20 as the highest quality flower ECS has produced to date and underscored the product’s fit within the premium segment.
This development complements ECS’s recent operational momentum, including sustained positive cash flow and strategic international shipments, reflecting a growing footprint in key export markets. The company’s approach to combining recognised genetics with Australian cultivation expertise may help it carve out a stronger position amid intensifying competition in the medicinal cannabis sector.
Bottom Line?
ECS’s launch of Gelonoidz #20 sets a high bar for Australian-grown premium cannabis, but the success of planned additional cultivars and export market traction will be critical to sustaining momentum.
Questions in the middle?
- How will Gelonoidz #20 perform commercially in both domestic and export markets?
- What regulatory or market hurdles could impact ECS’s plans for multiple Terphogz cultivar launches in FY27?
- To what extent can ECS leverage Terphogz branding to differentiate itself in a crowded medicinal cannabis market?